NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 3:00 p.m. ET/12:00 p.m. PT.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the expansion of its Advanced Materials Science™ (AMS) implant portfolio with the commercial launch of the Modulus® XLIF® Dual Sided Plate, and the receipt of 510(k) clearances from the U.S. Food and Drug Administration (FDA) for Modulus ALIF and Cohere® TLIF-O.
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the virtual BofA Securities 2020 Healthcare Conference on Tuesday, May 12 at 5:00 p.m. ET/2:00 p.m. PT.
NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering (the "Offering") of $400.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). NuVasive also granted to the initial purchasers of the Convertible Notes a 13-day option to purchase up to an additional $50.0 million aggregate principal amount of the Convertible Notes. The sale of the Convertible Notes to the initial purchasers is expected to settle on June 1, 2020, subject to customary closing conditions, and is expected to result in approximately $387.5 million in net proceeds to NuVasive after deducting fees and estimated offering expenses payable by NuVasive (assuming no exercise of the initial purchasers' option to purchase additional Convertible Notes).
All four locally based stocks that trade regularly on an exchange posted gains by the end of the trading session Monday.
Those holding NuVasive (NASDAQ:NUVA) shares must be pleased that the share price has rebounded 35% in the last thirty...
All four Dayton stocks that trade regularly on an exchange fared worse than the broad market by mid-afternoon Wednesday.
NuVasive, Inc. (NASDAQ: NUVA) announced today that it intends to offer (the "Offering"), subject to market and other considerations, $400.0 million aggregate principal amount of Convertible Senior Notes due 2023 (the "Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). NuVasive also intends to grant to the initial purchasers of the Convertible Notes a 13-day option to purchase up to an additional $50.0 million aggregate principal amount of the Convertible Notes.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today provided an update on actions the Company is taking to best position the business and support the Company's stakeholders in light of the COVID-19 pandemic.
NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.
NuVasive (NUVA) delivered earnings and revenue surprises of 37.14% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2020.
Markets rebounded aggressively Tuesday on hopes that Congress would finalize an estimated $2 trillion stimulus plan to stabilize the U.S. economy amid the novel coronavirus (COVID-19) pandemic.
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced its LessRay® radiation reduction and workflow enhancement platform won the "Best New Imaging Technology Solution" award in the 2020 MedTech Breakthrough Awards.
Image source: The Motley Fool. NuVasive Inc (NASDAQ: NUVA)Q1 2020 Earnings CallMay 6, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGreetings, and welcome to the NuVasive, Inc.
Q1 2020 NuVasive Inc Earnings Call